Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population.
Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population.
复制标题
DOI：
10.1186/1471-2334-9-207
复制
发表时间：
2009-12-15
影响因子：
3.7
通讯作者：
Kang YA
中科院分区：
文献类型：
--
作者：
Kim EY;Lim JE;Jung JY;Son JY;Lee KJ;Yoon YW;Park BH;Moon JW;Park MS;Kim YS;Kim SK;Chang J;Kang YA
Interferon-γ release assay (IGRA) may improve diagnostic accuracy for latent tuberculosis infection (LTBI). This study compared the performance of the tuberculin skin test (TST) with that of IGRA for the diagnosis of LTBI in immunocompromised patients in an intermediate TB burden country where BCG vaccination is mandatory. We conducted a retrospective observational study of patients given the TST and an IGRA, the QuantiFERON-TB Gold In-Tube (QFT-IT), at Severance Hospital, a tertiary hospital in South Korea, from December 2006 to May 2009. Of 211 patients who underwent TST and QFT-IT testing, 117 (55%) were classified as immunocompromised. Significantly fewer immunocompromised than immunocompetent patients had positive TST results (10.3% vs. 27.7%, p 0.001), whereas the percentage of positive QFT-IT results was comparable for both groups (21.4% vs. 25.5%). However, indeterminate QFT-IT results were more frequent in immunocompromised than immunocompetent patients (21.4% vs. 9.6%, p 0.021). Agreement between the TST and QFT-IT was fair for the immunocompromised group (κ = 0.38), but moderate agreement was observed for the immunocompetent group (κ = 0.57). Indeterminate QFT-IT results were associated with anaemia, lymphocytopenia, hypoproteinemia, and hypoalbuminemia. In immunocompromised patients, the QFT-IT may be more sensitive than the TST for detection of LTBI, but it resulted in a considerable proportion of indeterminate results. Therefore, both tests may maximise the efficacy of screening for LTBI in immunocompromised patients.
登录
查看更多内容
影响因子：
7.7
作者：
CYR, L;FRANCIS, K
通讯作者：
FRANCIS, K
DOI：
10.1164/rccm.200402-179oc
发表时间：
2004-07-01
影响因子：
24.7
作者：
Mori, T;Sakatani, M;Tsuyuguchi, I
通讯作者：
Tsuyuguchi, I
影响因子：
9.6
作者：
Richeldi, Luca;Losi, Monica;Fabbri, Leonardo M.
通讯作者：
Fabbri, Leonardo M.
DOI：
10.1164/rccm.200509-1516pp
发表时间：
2006-10-01
影响因子：
24.7
作者：
Richeldi, Luca
通讯作者：
Richeldi, Luca
DOI：
10.1164/rccm.200502-196oc
发表时间：
2005-09-01
影响因子：
24.7
作者：
Ferrara, G;Losi, M;Richeldi, L
通讯作者：
Richeldi, L